{"prompt": "['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '10.2.', 'Randomization', 'Participants will be randomized equally (1:1) to the two treatment arms of placebo and 35', 'mg danirixin HBr. Randomization will be stratified by smoking status (current VS.', 'former).', '10.3.', 'Populations for Analyses', 'For purposes of analysis, the following populations are defined:', 'Population', 'Description', 'All Participants', 'This population will comprise all participants screened and', 'for whom a record exists on the study database and will be', 'used for the tabulation and listing of reasons for withdrawal', 'before randomization and listings of AEs and SAEs for', 'nonrandomized participants.', 'Intent To Treat (ITT)', 'This population will comprise all participants randomized to', 'treatment and who received at least one dose of study', 'medication. This will constitute the primary population for all', 'analyses of efficacy and safety. Outcomes will be reported', 'according to the randomized treatment allocation.', 'Per-Protocol (PP)', 'This population will comprise of all patients in the ITT', 'Population', 'population who are not major protocol violators.', 'Safety', 'All randomized participants who take at least 1 dose of study', 'treatment. Participants will be analyzed according to the', 'treatment they actually received.', '10.4.', 'Statistical Analyses', 'Treatment comparisons using all endpoints will be made using appropriate statistical', 'techniques. Analysis methods for key endpoints are described below. Main analysis will', 'use ITT unless noted. Further details on all analyses will be described in the reporting and', 'analysis plan (RAP).', '10.4.1.', 'Efficacy Analyses', 'The total probability of success will be defined as a combination of a joint and', 'conditional statement. The joint probability of success will be defined as the probability', 'of the difference in the rate of decline in FEV1 between danirixin and placebo is greater', 'than or equal to 0 and the difference in the change in SGRQ total score from baseline', 'between danirixin and placebo is less than or equal to 0 is greater than 70%. If the joint', 'probability of success is less than 70%, success can further be defined based on each', 'endpoint independently, where either the difference in the rate of decline in FEV1 is', '47']['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'greater than or equal to 0 is greater than 80% or the difference in the change in SGRQ', 'total score is less than or equal to 0 is greater than 80%.', 'Total PoS = P(SFEV, SSGRQ 0) 70%', '+ P (OFEV1 SSGRQ 0) < 70%', '+P (65GRQ 0 & SSGRQ 0) < 70%', 'Endpoint', 'Statistical Analysis Methods', 'Primary', 'Rate of decline in FEV1 and change from baseline in SGRQ total score', 'Exploratory', 'Will be described in detail in the RAP', '48']['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Lung Function Decline: Rate of Decline of FEV1 (mL/yr)', 'The rate of decline of FEV1 will be derived from a repeated measures random', 'coefficients model. Post-baseline FEV will be modelled including terms for age, sex,', 'smoking status, FEV1 at baseline, and BMI along with treatment group, time and', 'treatment by time interaction as fixed effects. Subject will be a random effect. Time will', 'be defined as the number of days since start of treatment. Only FEV values measured', 'after baseline will be used in the model. Based on the results of previous studies, the', 'study team will determine the time point at which post-baseline spirometry assessments', 'will be included in the model to account for the initial treatment response. The estimate', 'of the rate of FEV1 decline will be the slope of the parameter estimate of the treatment by', 'time interaction term in the model. Contrasts will be calculated for the difference in', 'treatment by time interaction between danirixin and placebo treatment groups to estimate', 'the treatment difference.', 'FEV1 = Treatment group + age + sex +smoking status+FEV1_BL+BMI+ time +', '-', 'treatment*time', 'The rate of decline for each subject, the estimate of the slope parameter of the treatment', 'by time interaction term, will be used as a co-primary endpoint for the joint analysis', 'using both FEV1 and SGRQ.', 'HRQoL: SGRQ', 'A co-primary endpoint of interest is change in SGRQ total score (derived from SGRQ-C)', 'from baseline. Change in SGRQ total scores from baseline will be derived using a mixed', 'model with repeated measures (MMRM) including fixed effects of treatment group, age,', 'sex, smoking status, BMI, baseline SGRQ score, time as a categorical variable and a', 'treatment by time interaction term. Subject will be a random effect. Estimated treatment', 'differences at the end of one year will be obtained. The difference of the least square', 'mean change from baseline at 12 months will be derived. The adjusted SGRQ total score', 'change from baseline will used as the other co-primary endpoint for the joint analysis', 'using both FEV1 and SGRQ.', 'Joint Analysis', 'The joint analysis will use the ITT population with all available FEV1 rate of decline and', 'change in SGRQ data.', 'The rate of decline (the slope parameter from the random coefficients model) of FEV1,', 'along with the change in SGRQ from the MMRM model will be extracted for each', 'subject. These values will then be used to obtain MCMC approximations of the joint', 'posterior distribution of the treatment differences between FEV1 decline and change in', 'SGRQ between the danirixin and placebo groups. Based on the samples from the', 'posterior distribution, the proportion of samples falling within certain treatment', 'difference regions will be calculated and the probability of success will be derived.', '49']\n\n###\n\n", "completion": "END"}